vs
FULTON FINANCIAL CORP(FULT)与Orthofix Medical Inc.(OFIX)财务数据对比。点击上方公司名可切换其他公司
FULTON FINANCIAL CORP的季度营收约是Orthofix Medical Inc.的1.5倍($336.2M vs $219.9M),FULTON FINANCIAL CORP净利率更高(28.2% vs -1.0%,领先29.2%),FULTON FINANCIAL CORP同比增速更快(4.2% vs 2.0%),过去两年Orthofix Medical Inc.的营收复合增速更高(8.0% vs 0.2%)
富尔顿金融公司是美国的区域性金融服务控股企业,总部位于宾夕法尼亚州兰开斯特市,主要为当地及周边区域提供多元化的金融相关服务,在区域金融市场拥有稳定的业务布局。
Orthofix医疗是全球知名骨科医疗器械企业,专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品,服务全球多地的骨科医师与医疗机构,致力于提升肌肉骨骼疾病患者的诊疗效果。
FULT vs OFIX — 直观对比
营收规模更大
FULT
是对方的1.5倍
$219.9M
营收增速更快
FULT
高出2.2%
2.0%
净利率更高
FULT
高出29.2%
-1.0%
两年增速更快
OFIX
近两年复合增速
0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $336.2M | $219.9M |
| 净利润 | $94.8M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 28.2% | -1.0% |
| 营收同比 | 4.2% | 2.0% |
| 净利润同比 | -4.3% | 92.4% |
| 每股收益(稀释后) | $0.55 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
FULT
OFIX
| Q1 26 | $336.2M | — | ||
| Q4 25 | $336.0M | $219.9M | ||
| Q3 25 | $334.6M | $205.6M | ||
| Q2 25 | $324.1M | $203.1M | ||
| Q1 25 | $318.4M | $193.6M | ||
| Q4 24 | $319.6M | $215.7M | ||
| Q3 24 | $317.7M | $196.6M | ||
| Q2 24 | $334.7M | $198.6M |
净利润
FULT
OFIX
| Q1 26 | $94.8M | — | ||
| Q4 25 | $99.0M | $-2.2M | ||
| Q3 25 | $100.5M | $-22.8M | ||
| Q2 25 | $99.2M | $-14.1M | ||
| Q1 25 | $93.0M | $-53.1M | ||
| Q4 24 | $68.6M | $-29.1M | ||
| Q3 24 | $63.2M | $-27.4M | ||
| Q2 24 | $95.0M | $-33.4M |
毛利率
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | 35.7% | 0.2% | ||
| Q3 25 | 38.2% | -8.3% | ||
| Q2 25 | 37.8% | -7.9% | ||
| Q1 25 | 36.1% | -25.2% | ||
| Q4 24 | 27.0% | -5.3% | ||
| Q3 24 | 25.1% | -9.6% | ||
| Q2 24 | 30.8% | -12.5% |
净利率
FULT
OFIX
| Q1 26 | 28.2% | — | ||
| Q4 25 | 29.5% | -1.0% | ||
| Q3 25 | 30.0% | -11.1% | ||
| Q2 25 | 30.6% | -6.9% | ||
| Q1 25 | 29.2% | -27.4% | ||
| Q4 24 | 21.5% | -13.5% | ||
| Q3 24 | 19.9% | -13.9% | ||
| Q2 24 | 28.4% | -16.8% |
每股收益(稀释后)
FULT
OFIX
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.53 | $-0.05 | ||
| Q3 25 | $0.53 | $-0.57 | ||
| Q2 25 | $0.53 | $-0.36 | ||
| Q1 25 | $0.49 | $-1.35 | ||
| Q4 24 | $0.36 | $-0.76 | ||
| Q3 24 | $0.33 | $-0.71 | ||
| Q2 24 | $0.52 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.5B | $450.0M |
| 总资产 | $32.2B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益
FULT
OFIX
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $450.0M | ||
| Q3 25 | $3.4B | $442.5M | ||
| Q2 25 | $3.3B | $458.3M | ||
| Q1 25 | $3.3B | $458.3M | ||
| Q4 24 | $3.2B | $503.1M | ||
| Q3 24 | $3.2B | $525.9M | ||
| Q2 24 | $3.1B | $546.0M |
总资产
FULT
OFIX
| Q1 26 | $32.2B | — | ||
| Q4 25 | $32.1B | $850.6M | ||
| Q3 25 | $32.0B | $832.6M | ||
| Q2 25 | $32.0B | $837.2M | ||
| Q1 25 | $32.1B | $823.1M | ||
| Q4 24 | $32.1B | $893.3M | ||
| Q3 24 | $32.2B | $867.9M | ||
| Q2 24 | $31.8B | $882.0M |
负债/权益比
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势,按日历期对齐
经营现金流
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | $304.5M | $27.7M | ||
| Q3 25 | $116.1M | $12.4M | ||
| Q2 25 | $91.7M | $11.6M | ||
| Q1 25 | $703.0K | $-18.4M | ||
| Q4 24 | $416.6M | $23.7M | ||
| Q3 24 | $-22.0M | $11.7M | ||
| Q2 24 | $157.8M | $9.0M |
自由现金流
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率
FULT
OFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 6.07× | — | ||
| Q3 24 | -0.35× | — | ||
| Q2 24 | 1.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FULT
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |